What is CUSIP 451033203?

CUSIP 451033203 is the security identifier used in SEC filing datasets for IBIO - iBio, Inc. - Common Stock.

Who owns IBIO - iBio, Inc. - Common Stock based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

Security Snapshot

iBio, Inc. - Common Stock (IBIO) Institutional Ownership

CUSIP: 451033203

13F Institutional Holders and Ownership History from Q2 2018 to Q1 2023

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock
Symbol: IBIO on NYSE
Shares outstanding: 34,413,043

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Filing notes and source

Key facts

IBIO - iBio, Inc. - Common Stock is tracked under CUSIP 451033203.
13F reference-period holder data is not available.
4 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder data for the Q2 2026 reference period is not available.
Available periods remain in the history table; they do not substitute for the headline period.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

451033203

13F reference period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

IBIO full holder history iBio, Inc. SEC filings iBio, Inc. company facts iBio, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 451033203:

Q1 2023 (0 holders) Q4 2022 (1 holder) Q3 2022 (34 holders) Q2 2022 (44 holders) Q1 2022 (66 holders) Q4 2021 (74 holders) Q3 2021 (81 holders) Q2 2021 (81 holders) Q1 2021 (91 holders) Q4 2020 (86 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

IBIO

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
Cormorant Asset Management, LP	10%		3,834,335	Cormorant Asset Management, LP	31 Mar 2026
Frazier Life Sciences Public Fund, L.P.	5.7%		1,953,467	Frazier Life Sciences Public Fund, L.P.	31 Mar 2026
EcoR1 Capital, LLC	4.6%		1,583,000	EcoR1 Capital, LLC	31 Mar 2026
SABBY MANAGEMENT, LLC	0.2%	$3,272	19,250	SABBY MANAGEMENT, LLC	31 Dec 2024

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Headline period

n/a

Rows shown

1-20 of 20

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2023 Q1	0	$0	-$3,555				0
2022 Q4	8,000	$3,555	-$4,960,472	$0	$0	$0.44	1
2022 Q3	28,854,191	$4,912,153	-$101,983	$57,000	$49,000	$0.17	34
2022 Q2	28,893,785	$7,628,584	-$3,666,548	$95,000	$111,000	$0.26	44
2022 Q1	40,898,667	$17,488,990	-$2,068,575	$176,000	$186,000	$0.43	66
2021 Q4	45,417,667	$25,020,191	+$41,852	$562,000	$243,000	$0.55	74
2021 Q3	44,703,059	$47,552,296	+$1,210,624	$1,489,000	$604,000	$1.06	81
2021 Q2	43,383,633	$65,497,510	-$1,744,149	$3,339,000	$1,723,000	$1.51	81
2021 Q1	44,512,797	$68,540,610	+$21,890,326	$2,285,000	$1,468,000	$1.54	91
2020 Q4	30,300,041	$31,829,858	+$14,847,235	$865,000	$447,000	$1.05	86
2020 Q3	15,950,862	$32,391,539	+$11,611,320	$960,000	$584,000	$2.03	76
2020 Q2	10,174,491	$22,597,868	+$15,893,478			$2.22	56
2020 Q1	3,058,367	$3,241,000	+$2,177,563			$1.06	23
2019 Q4	1,295,868	$324,000	+$213,498			$0.25	12
2019 Q3	362,140	$195,000	+$4,117			$0.54	10
2019 Q2	329,524	$233,000	+$19,399			$0.70	11
2019 Q1	302,586	$265,000	+$52,953			$0.89	10
2018 Q4	240,712	$181,000	-$58,314			$0.75	9
2018 Q3	322,517	$275,000	-$95,968			$0.85	14
2018 Q2	434,676	$392,000	+$392,000			$0.90	9